Activated Phosphoinositide 3 Kinase Delta Syndrome (apds) Therapeutics
1. Joenja patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 24, 2028 |
| New Patient Population(NPP) | Sep 11, 2029 |
| New Strength(NS) | Sep 11, 2029 |
| ODE*(ODE*) | Mar 24, 2030 |
| Orphan Drug Exclusivity(ODE-430) | Mar 24, 2030 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 25 March, 2027
Market Authorisation Date: 11 September, 2026
Dosage: TABLET
More Information on Dosage
JOENJA family patents
